DEMYSTIFIED

Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications

S Badve¹ and H Nakshatri²

¹ Departments of Pathology and Laboratory Medicine, and Internal Medicine, Walther Oncology Center, Indiana University School of Medicine, Indianapolis, Indiana, USA
² Departments of Surgery, Biochemistry and Molecular Biology, Walther Oncology Center, Indiana University School of Medicine, Indianapolis, Indiana, USA

Correspondence to:
Sunil Badve, Clarian Pathology Laboratory, 350 West 11th Street, 4th Floor, Indianapolis, IN 46202, USA; sbadve{at}iupui.edu

The oestrogen receptor (ER) pathway is key for survival and progression in a significant proportion of breast cancers. The ER can be activated by oestrogen or activated due to "crosstalk" with growth factor receptor pathways. Activated ER signals through transcriptional and non-transcriptional mechanisms. Immunohistochemistry (IHC), in spite of the shortcomings, remains the method of choice as it provides for in situ assessment of ER expression within the tumour cells. This capability is lost in tissue grinding methods that assess oestrogen-binding activity or messenger RNAs in tumours. IHC is also not influenced by the presence of non-tumoural cells or low amounts of tumour cells within samples examined. It is clear that ER-positive tumours do not represent a single entity. Irrespective of the terminology used, low-grade ER-positive (also known as luminal A) tumours need to be differentiated from high-grade/highly proliferative ER-positive tumours. This can be done in a variety of ways including but not limited to analysis of FOXA1 and GATA-3 by IHC, and limited molecular profiling by Oncotype DX, MGH2-gene signature, intrinsic gene signature or MapQuant Dx. Several areas of ER biology are still poorly understood; these include: its function in the cytoplasm/plasma membrane, its role in the differentiation to proliferation switch, and pathways associated with resistance to hormonal therapy. A detailed understanding of these areas will permit better classification and a personalised approach to management of ER-positive breast cancers.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?